Business Standard

Thursday, December 26, 2024 | 09:07 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

India drug regulator asks Dr Reddy's for more data on Sputnik V vaccine

The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study

Sputnik V, Dr Reddy’s Laboratories, DRL, coronavirus, vaccine, covid-19
Premium

Dr.Reddy's has been conducting small clinical trials with Sputnik V in India under a deal with Russia's wealth fund

Reuters
An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.
 
The committee asked https://bit.ly/3fXSUKT the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study, as well as data on serious adverse events and positive cases reported till date.

Dr.Reddy's has been conducting small clinical trials with Sputnik V in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in